Tubacin (Synonyms: HDAC6) |
Catalog No.GC16386 |
Tubacin (tubulin acetylation inducer) is a small molecule that selectively inhibits histone deacetylase 6 (HDAC6) and induces acetylation of α-tubulin with IC50 of 0.004µM
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 537049-40-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
canine renal epithelial cells MDCK.2 cells |
Preparation Method |
Confluent MDCK.2 cells were split 1:10 in 10-cm dishes. After 24 hours, the cells were again split, resuspended in 10 ml of medium, and pelleted. They were resuspended in 2 ml of medium, and 2 × 104 cells were mixed with growth factor-reduced Matrigel (1.5%) and collagen I (1.5%), MEM (1×), HEPES (20 µM), and NaHCO3 (0.24%). The Matrigel/collagen I/cell mixture was plated in 24-well plates (450 µl/well) and allowed to solidify for 30 minutes at 37°C before being overlaid with 500 µl of medium. Cells were treated with tubacin, tubastatin-A, or DMSO dissolved in medium on days 0, 2, 4, 6, 8, 10, 12, and 14 after old medium was removed. |
Reaction Conditions |
10 µM for 0-14 d |
Applications |
Treated the cells with tubacin on days 0, 2, 4, 6, 8, 10, 12, and 14, and this treatment did indeed prevent cyst formation. treated the cells only once with tubacin, on day 0, this single treatment alone slowed the cyst growth. |
Animal experiment [2]: | |
Animal models |
Colitis models |
Preparation Method |
Freshly prepared 4% (wt/vol) dextran sodium sulfate (DSS) was added daily for 5 days to the pH-balanced tap water of WT B6 mice. Mice were treated daily for 7 days with tubacin or niltubacin (0.5 mg/kg of body weight/day, i.p.), and colitis was assessed by daily monitoring of body weight, stool consistency, and fecal blood. Stool consistency was scored as 0 (hard), 2 (soft), or 4 (diarrhea), and fecal blood (Hemoccult) was scored as 0 (absent), 2 (occult), or 4 (gross). |
Dosage form |
Intraperitoneal injection, 0.5 mg/kg/day |
Applications |
Tubacin-treated mice were protected against development of weight loss and diarrhea, and this effect was Treg dependent. |
References: [1]: Cebotaru L, Liu Q, Yanda M K, et al. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease[J]. Kidney international, 2016, 90(1): 90-99. |
Tubacin (tubulin acetylation inducer) is a small molecule that selectively inhibits histone deacetylase 6 (HDAC6) and induces acetylation of α-tubulin with IC50 of 0.004µM [1,2]. Tubacin also inhibited HDAC1 with IC50 of 1.4µM [2].
Tubacin preferentially induced α-tubulin hyperacetylation at 2.5 µM in BMSCs. Tubacin induces α-tubulin acetylation at 5 µM and protects prostate cancer (LNCaP) cells from hydrogen peroxide-induced death at 8 µM via peroxiredoxin acetylation [2]. Tubacin (0.25 µM and 0.5 µM) with a low concentrationcould promote BMSC adhesion, proliferation and migration, and tubacin can upregulate the protein levels of VCAM-1, ICAM-1, p-ERK, and acetylated α-tubulin [3]. Incubation with tubacin for 24 h increased the amount of Tumor-derived extracellular vesicles (EVs) in the conditioned media of both FEMX-I and Caco-2 cells by 6.6- and 2.1-fold, respectively [4]. Tubacin significantly altered the cellular lipid composition, which could promote release of CD133+ EVs in FEMX-1 and Caco-2 cells [4].
Tubacin (5 mg/kg, i.p.) significantly increased both mRNA and protein levels for eNOS in the aorta of mice, in the presence of NO donor sodium nitroprusside, tubacin's effects on Ach-mediated vasorelaxation were largely abolished [5]. Pretreatment with tubacin (5 mg/kg, i.p.) significantly reduced cerebral infarct size and the severity of cortical edema at 24 h after arterial occlusion [5]. Tubacin (5 mg/kg) administration significantly reduced the kidney growth in a very aggressive murine model of polycystic kidney disease (PKD)that features the development of giant polycystic kidneys at 3 weeks of age [6].
References:
[1]. Aldana-Masangkay G I, Rodriguez-Gonzalez A, Lin T, et al. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells[J]. Leukemia & lymphoma, 2011, 52(8): 1544-1555.
[2]. Butler K V, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A[J]. Journal of the American Chemical Society, 2010, 132(31): 10842-10846.
[3]. Liang J Q, Lu F, Gan B, et al. Low-dose tubacin promotes BMSCs proliferation and morphological changes through the ERK pathway[J]. American Journal of Translational Research, 2019, 11(3): 1446.
[4]. Chao O S, Chang T C, Di Bella M A, et al. The HDAC6 inhibitor tubacin induces release of CD133+ extracellular vesicles from cancer cells[J]. Journal of Cellular Biochemistry, 2017, 118(12): 4414-4424.
[5]. Chen J, Zhang J, Shaik N F, et al. The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase[J]. Journal of Biological Chemistry, 2019, 294(51): 19565-19576.
[6]. Cebotaru L, Liu Q, Yanda M K, et al. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease[J]. Kidney international, 2016, 90(1): 90-99.
Cas No. | 537049-40-4 | SDF | |
Synonyms | HDAC6 | ||
Chemical Name | N-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide | ||
Canonical SMILES | C1C(OC(OC1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6 | ||
Formula | C41H43N3O7S | M.Wt | 721.86 |
Solubility | ≥ 7.19mg/mL in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.3853 mL | 6.9266 mL | 13.8531 mL |
5 mM | 0.2771 mL | 1.3853 mL | 2.7706 mL |
10 mM | 0.1385 mL | 0.6927 mL | 1.3853 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *